Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?

I read with interest the study by Kim et  al.,1 comparing stereotactic body radiation therapy (SBRT) to radiofrequency ablation (RFA) in Asian patients with hepatocellular carcinoma (HCC). In this retrospective multicenter study, the cohort included 2,064 patients: 1,568 and 496 in the RFA and SBRT groups, respectively. More than half of the patients (56.5%) had developed recurrent tumors, mainly after transarterial chemoembolization (TACE, 44.8%). To adjust for unbalanced clinical factors, propensity score matching was performed, which resulted in 313 in each group.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research